Dr Eleanor Cheadle (PhD, BSc (Hons), FHEA) - research
My research interests lie in immunotherapy of B-cell malignancies. I am particularly interested in ways to improve the generation of effective anti-tumour T-cell immune responses post anti-CD20 monoclonal antibody therapy. My research currently focuses on a number of ways to improve anti-CD20 mAb therapy such as combining therapy with immunomodulatory agents, radiation and manipulation of the tumour microenvironment. We are particularly interested in enhancing the efficacy of the novel type II anti-CD20 mAb obinutuzumab. I am also interested in adoptive cell therapy, in particular gene modified T-cells expressing CD19 specific chimeric antigen receptors.
Collaborators and affiliated staff
- Improving CAR T Cell Therapy to Treat CD19+ Malignancies.
- Increasing the Efficacy of Anti-CD20 Antibody Therapy and Improving Outcome in B-Cell Response Malignancies by Enhancing the Anti-Tumour Immune Response.
- Increasing the efficacy of the type II anti -CD20 mAb GA101 by enhancing the anti-tumour immune response in the hCD20 transgenic mouse model
- Preparation and Testing of a Recombinant BCG Vaccine for Childhood ALL Expressing the TEL-AML1 (ETV6-RUNX1) Oncoprotein.